英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
flytte查看　flytte　在百度字典中的解释百度英翻中〔查看〕
flytte查看　flytte　在Google字典中的解释Google英翻中〔查看〕
flytte查看　flytte　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Frontiers | Benefits of SGLT2 inhibitors in patients with . . .
    SGLT2 inhibitors have transformed the care of patients with diabetes, chronic kidney disease (CKD), and cardiovascular disease Nevertheless, the efficacy of
  • Sodium-Glucose Transport 2 (SGLT2) Inhibitors
    Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, have transformed the management of type 2 diabetes mellitus (T2DM) by providing glucose-lowering efficacy together with cardiovascular and renal protection Initially approved as adjuncts to diet and exercise for glycemic control, these agents now have expanded
  • Cardiometabolic and renal benefits of sodium–glucose . . .
    In the past decade, the therapeutic scope of sodium–glucose cotransporter 2 (SGLT2) inhibitors has expanded beyond glycaemic regulation in the management of type 2 diabetes mellitus In this
  • Safe and Appropriate Prescribing of SGLT2 inhibitors in . . .
    With SGLT2 inhibitors, DKA may occur with relatively ‘normal’ glucose levels (Euglycemic DKA), which is atypical and may delay diagnosis and treatment Before starting an SGLT2 inhibitor, assess the risk of DKA and address modifiable risk factors
  • 11. Chronic Kidney Disease and Risk Management: Standards of . . .
    Moreover, recent data support the notion that SGLT2 inhibitors reduce oxidative stress in the kidney by >50% and blunt increases in angiotensinogen as well as reduce NLRP3 inflammasome activity (92–94) Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) have also been shown to improve kidney outcomes (95–100)
  • New Medications for Type 2 Diabetes and Kidney Disease: SGLT2 . . .
    Learn about FDA-approved medications, SGLT2 inhibitors, Finerenone, and GLP-1 RA, that are effective for patients with type 2 diabetes and kidney disease or early-stage kidney disease
  • SGLT2 Inhibitors – The New Standard of Care for . . . - Springer
    A substantial evidence base supports the use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in the treatment of type 2 diabetes mellitus (T2DM) This class of medicines has demonstrated important benefits that extend beyond glucose-lowering efficacy to protective mechanisms capable of slowing or preventing the onset of long-term cardiovascular, renal and metabolic (CVRM) complications
  • A critical review on SGLT2 inhibitors for diabetes mellitus . . .
    Future medical research should evaluate SGLT2 inhibitor usage as a component of combined drug treatment approaches for patients with polygenic diseases between diabetes and cardiovascular conditions to achieve better results alongside minimal adverse reactions
  • SGLT2 Inhibitors: What They Are, Uses Side Effects
    SGLT2 inhibitors lower blood sugar by causing your kidneys to remove glucose through your pee Learn more about this treatment for Type 2 diabetes





中文字典-英文字典  2005-2009